# Kailera Therapeutics Inc. (KLRA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $16.23, market value $2.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Kailera Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: 41.8%**. 41.8% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Financial health
- **Current ratio: 12.01** (quick 12.01). Current assets cover the next year's liabilities 12.01 times.

## Dividends
- **Dividend: none**. Kailera Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -42.5%** (7.1% above the low). Trading 43% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 1.23** (volatility 67%). Beta of 1.23 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=KLRA · Page: https://foliofundamentals.com/stocks/klra

Not investment advice.